The Pfizer mRNA Vaccine: Pharmacokinetics and Toxicity?


The dangers of the COVID-19 vaccine spike protein and its interactions with the human immune system, involving the risk of blood clots and leaky blood vessels, are becoming better known.

Dangers in the body?

But how far can such dangers spread in the body? What does this mean for the safety of vaccines?

And what about the vaccine’s lipid nanoparticles (LNPs), which are made of lipids that have never been injected into a human?

What does the evidence to date tell us about the pharmacokinetics of the vaccines and the toxicity of their components? Why are the vaccines expected to cause the following:

  • Blood clotting shortly after vaccination, which can lead to heart attack, stroke, and venous thrombosis
  • Severe damage to female fertility
  • Severe damage to breastfed infants
  • Cumulative toxicity after multiple injections?

In this detailed analysis, Associate Professor Michael Palmer and Professor Sucharit Bhakdi explain. They write:

We summarize the results of an animal study submitted by Pfizer to Japanese health authorities in 2020 that focused on the distribution and elimination of an mRNA model vaccine. We show that this study clearly anticipated serious blood clotting risks and other adverse effects. The failure to monitor and evaluate these risks in subsequent clinical trials and the grossly negligent review process associated with emergency approvals have predictably led to an unprecedented medical disaster.

Of particular concern is the very slow elimination of toxic cationic lipids. In individuals repeatedly injected with mRNA vaccines containing these lipids-whether directed against COVID or another pathogen or disease-this would result in cumulative toxicity. There is a real possibility that the cationic lipids could accumulate in the ovaries. The serious risk to female fertility associated with this requires urgent attention by the public and health authorities.

Attachment

The Pfizer mRNA vaccine